Johnson & Johnson (JNJ) stock
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3086% above fair value
$278.70−3.85 (-1.36%)
Close on Nov 17, 2026Market cap $670.92BP/E 42.3Yield 1.84%
Johnson & Johnson total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Johnson & Johnson's total debt was $44.65B at Sep 27, 2026. For fiscal 2025 it was $47.94B, up 30.8% from the year before. Over ten years it grew 9.2% a year on average. The highest annual figure on record is $47.94B in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $47.94B | +30.8% |
| FY2024 | Dec 29, 2024 | $36.65B | +24.7% |
| FY2023 | Dec 31, 2023 | $29.38B | -26.0% |
| FY2022 | Jan 1, 2023 | $39.69B | +17.5% |
| FY2021 | Jan 2, 2022 | $33.79B | -4.1% |
| FY2020 | Jan 3, 2021 | $35.24B | +27.2% |
| FY2019 | Dec 29, 2019 | $27.69B | -9.2% |
| FY2018 | Dec 30, 2018 | $30.48B | -11.8% |
| FY2017 | Dec 31, 2017 | $34.58B | +27.4% |
| FY2016 | Jan 1, 2017 | $27.14B | +36.7% |
| FY2015 | Jan 3, 2016 | $19.86B | +6.1% |
| FY2014 | Dec 28, 2014 | $18.72B | +2.7% |
| FY2013 | Dec 29, 2013 | $18.23B | +12.6% |
| FY2012 | Dec 30, 2012 | $16.19B | -17.7% |
| FY2011 | Jan 1, 2012 | $19.67B | +17.4% |
| FY2010 | Jan 2, 2011 | $16.76B | +15.0% |
| FY2009 | Jan 3, 2010 | $14.58B | +23.0% |
| FY2008 | Dec 28, 2008 | $11.85B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $44.65B | -2.5% |
| Q2 FY2026 | Jun 28, 2026 | $49.04B | -3.4% |
| Q1 FY2026 | Mar 29, 2026 | $54.99B | +5.2% |
| Q4 FY2025 | Dec 28, 2025 | $47.94B | +30.8% |
| Q3 FY2025 | Sep 28, 2025 | $45.80B | +28.1% |
| Q2 FY2025 | Jun 29, 2025 | $50.76B | +22.3% |
| Q1 FY2025 | Mar 30, 2025 | $52.25B | +55.4% |
| Q4 FY2024 | Dec 29, 2024 | $36.65B | +24.7% |
| Q3 FY2024 | Sep 29, 2024 | $35.75B | +19.5% |
| Q2 FY2024 | Jun 30, 2024 | $41.49B | -9.0% |
| Q1 FY2024 | Mar 31, 2024 | $33.63B | -36.4% |
| Q4 FY2023 | Dec 31, 2023 | $29.38B | -26.0% |
| Q3 FY2023 | Oct 1, 2023 | $29.92B | -6.6% |
| Q2 FY2023 | Jul 2, 2023 | $45.60B | +39.9% |
| Q1 FY2023 | Apr 2, 2023 | $52.91B | +59.6% |
| Q4 FY2022 | Jan 1, 2023 | $39.69B | +17.5% |
| Q3 FY2022 | Oct 2, 2022 | $32.03B | -5.6% |
| Q2 FY2022 | Jul 3, 2022 | $32.60B | -2.6% |
| Q1 FY2022 | Apr 3, 2022 | $33.15B | -1.4% |
| Q4 FY2021 | Jan 2, 2022 | $33.79B | -4.1% |
| Q3 FY2021 | Oct 3, 2021 | $33.93B | -10.1% |
| Q2 FY2021 | Jul 4, 2021 | $33.48B | +10.2% |
| Q1 FY2021 | Apr 4, 2021 | $33.61B | +21.9% |
| Q4 FY2020 | Jan 3, 2021 | $35.24B | +27.2% |
| Q3 FY2020 | Sep 27, 2020 | $37.76B | +29.2% |
| Q2 FY2020 | Jun 28, 2020 | $30.39B | +3.3% |
| Q1 FY2020 | Mar 29, 2020 | $27.58B | -6.1% |
| Q4 FY2019 | Dec 29, 2019 | $27.69B | -9.2% |
| Q3 FY2019 | Sep 29, 2019 | $29.22B | -6.5% |
| Q2 FY2019 | Jun 30, 2019 | $29.42B | -8.3% |
| Q1 FY2019 | Mar 31, 2019 | $29.37B | -9.7% |
| Q4 FY2018 | Dec 30, 2018 | $30.48B | -11.8% |
| Q3 FY2018 | Sep 30, 2018 | $31.25B | -11.1% |
| Q2 FY2018 | Jul 1, 2018 | $32.08B | -7.2% |
| Q1 FY2018 | Apr 1, 2018 | $32.53B | +0.5% |
| Q4 FY2017 | Dec 31, 2017 | $34.58B | +27.4% |
| Q3 FY2017 | Oct 1, 2017 | $35.17B | – |
| Q2 FY2017 | Jul 2, 2017 | $34.57B | – |
| Q1 FY2017 | Apr 2, 2017 | $32.37B | – |
| Q4 FY2016 | Jan 1, 2017 | $27.14B | – |
See a number that looks wrong?